Program
NB-003
Also written as “NB003” and “NB003 tablets”.
Its studies are mostly in Gastrointestinal Stromal Tumors, led by Ningbo Newbay Technology Development.
Furthest: phase 3, since Jan 23, 20262 company-led studies, 1 open or runningNext primary completion: Aug 1, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ningbo Newbay Technology Development | 21 open or running | phase 3since Jan 23, 2026 | Jun 3, 2021 | Aug 1, 2028phase 3 · NCT07379047 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 3, 2021First study: phase 1 study in Advanced Solid TumorFirst studyNCT04936178 · 258 enrolled · United States, China, France and more
- Jan 23, 2026Phase 3 study in Gastrointestinal Stromal TumorsPhase 3 reachedNCT07379047 · 255 planned · China, South Korea
Ahead
- Aug 1, 2028Primary completion: phase 3 study in Gastrointestinal Stromal TumorsNCT07379047
TargetBeta
KIT →read by rule
“The tosylate salt form of NB003, an orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR; CD117), ”NCIt, by rule
Other programs on KIT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| imatinibrule | Novartis | phase 4 | 70 |
| regorafenibrule | Bayer | phase 4 | 40 |
| Avapritinibrule | Sanofi | phase 4 | 10 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| masitinibrule | AB Science | phase 3 | 38 |
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| ripretinibrule | Ono Pharmaceutical | phase 3 | 9 |
| velzatinib | GlaxoSmithKline | phase 3 | 8 |
| seralutinibrule | gb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-inc | phase 3 | 8 |
| elenestinib | Sanofi | phase 3 | 3 |
| briquilimabrule | jasper-therapeutics-inc | phase 2 | 7 |
| BLU-808 | Sanofi | phase 2 | 3 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07379047Gastrointestinal Stromal Tumors · China, South Korea | 3 | Recruiting | Aug 1, 2028 | 255 |
| NCT04936178Advanced Solid Tumor · United States, China, France and more | 1 | Completed | Aug 1, 2025 | 258 |
How it is read
Names in the registry
- “NB003”, 1 entry
- “NB003 tablets”, 1 entry
Conditions, from the studies’ own filings
- Gastrointestinal Stromal Tumors, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.